Skip to main content

Veradermics, Inc

corporate_fare Company Profile

Veradermics, Inc

MANE·NYSE·Life Sciences·CIK 0001827635

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for prevalent aesthetic and dermatological conditions. Our initial focus is on developing better treatments for PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and often result in high rates of treatment failure, patient dissatisfaction, and discontinuation. Patients and healthcare providers frequently cite slow onset of hair growth, inconsistent results, insufficient hair density, tolerability issues related to hormonal, mood, and cardiac side effects, inconvenient administration, and limited FDA-approved options (with no FDA-approved oral options for women) as shortcomings. We are developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent. While immediate release (IR) oral minoxidil was originally for resistant hypertension and used off-label for PHL, its release profile was not designed for hair growth, requiring lower doses to reduce cardiac stimulation. VDPHL01 utilizes minoxidil's validated hair growth biology through a novel and proprietary ER formulation designed to maximize total plasma concentrations of minoxidil for hair growth without inducing changes in cardiac activity.

Veradermics, Inc (NYSE:MANE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for MANE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 10 rated 8 or above. Recent SEC coverage for MANE spans 4, 10-Q, 8-K, SCHEDULE 13D/A.

Recent high-impact activity:

  • Veradermics Director Enright Sells $75.2M in Stock at $150.38
  • Veradermics 10-Q: $798.4M Cash Into 2030, Q3 Loss $21.0M, New 10b5-1 Plans
  • Veradermics Posts $21.0M Q3 Loss, $798.4M Cash Funds Operations Into 2030
  • Veradermics' Oral Hair-Loss Pill Deepens Hair Count at 12 Months in Phase 3 Study
  • Veradermics Sets Nov. 9 Call to Unveil 12-Month Phase 3 '302' Hair Loss Data

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$70M
Diluted EPS
-$111.91
Op. Cash Flow
-$71.6M
Free Cash Flow
-$71.63M
Operating Income
-$72.35M
Cash & Equivalents
$21.77M
Debt / Equity
0.00×
Shares Outstanding
749.76K sh
Source: 10-K · filed 2026-03-30 · accession 0001827635-26-000013

Short Interest & Short Volume

5.06 days to cover

FINRA reported short interest of 3,389,250 shares in MANE as of the October 30, 2026 settlement, a 8.4% decrease from the prior period — about 5.1 days to cover at its recent average daily volume. On November 20, 2026, 76.3% of MANE volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)3,389,250 shares as of October 30, 2026
Change vs prior period▼ 8.4%
Days to cover5.06 at avg daily volume of 670,314
Daily short volume (FINRA facilities)76.3% of 140,982 shares on November 20, 2026
5-day average short volume78.4%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Low risk

Filing-implied dilution signals for MANE, detected from its recent SEC filings.

1 shelf registration

Massive Resale Registration · No Proceeds to Company

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with M →
$118.49 -0.86% today
52-week range · as of 2026-11-13 $32 – $156.63
Market cap
$5.04B
Volume
375K (0.6× avg)
3-mo avg 676.2K
Live data · 2026-11-21 12:30 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MANE - Latest Insights

MANE
Nov 13, 2026, 5:39 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $129.66
Real-time Price: $118.49 info
Change: -$11.17 (-9%) info
Market Cap: $5.043B info
MANE
Nov 10, 2026, 4:57 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $148.44
Real-time Price: $118.49 info
Change: -$29.95 (-20%) info
Market Cap: $5.043B info
MANE
Nov 10, 2026, 8:54 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $142.72
Real-time Price: $118.49 info
Change: -$24.23 (-17%) info
Market Cap: $5.043B info
MANE
Nov 09, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $142.00
Real-time Price: $118.49 info
Change: -$23.51 (-17%) info
Market Cap: $5.043B info
MANE
Nov 08, 2026, 6:00 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $139.33
Real-time Price: $118.49 info
Change: -$20.84 (-15%) info
Market Cap: $5.043B info
MANE
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $108.01
Real-time Price: $118.49 info
Change: +$10.48 (+10%) info
Market Cap: $5.043B info
MANE
Oct 18, 2026, 6:00 PM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $108.82
Real-time Price: $118.49 info
Change: +$9.67 (+9%) info
Market Cap: $5.043B info
MANE
Aug 21, 2026, 6:32 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $102.82
Real-time Price: $118.49 info
Change: +$15.67 (+15%) info
Market Cap: $5.043B info
MANE
Aug 21, 2026, 6:11 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $102.82
Real-time Price: $118.49 info
Change: +$15.67 (+15%) info
Market Cap: $5.043B info
MANE
Aug 17, 2026, 5:30 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $108.22
Real-time Price: $118.49 info
Change: +$10.27 (+9%) info
Market Cap: $5.043B info
MANE
Aug 11, 2026, 7:40 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $110.00
Real-time Price: $118.49 info
Change: +$8.49 (+8%) info
Market Cap: $5.043B info
MANE
Aug 07, 2026, 5:08 PM EDT
Filing Type: S-1
Importance Score:
7
Price at Filing: $116.00
Real-time Price: $118.49 info
Change: +$2.49 (+2%) info
Market Cap: $5.043B info
MANE
Jul 15, 2026, 9:03 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $118.32
Real-time Price: $118.49 info
Change: +$0.1662 (+0.14%) info
Market Cap: $5.043B info
MANE
Jul 15, 2026, 8:54 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $119.00
Real-time Price: $118.49 info
Change: -$0.510 (-0.43%) info
Market Cap: $5.043B info
MANE
May 12, 2026, 5:11 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $103.90
Real-time Price: $118.49 info
Change: +$14.59 (+14%) info
Market Cap: $5.043B info
MANE
May 12, 2026, 5:06 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $103.90
Real-time Price: $118.49 info
Change: +$14.59 (+14%) info
Market Cap: $5.043B info
MANE
May 12, 2026, 8:32 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $111.00
Real-time Price: $118.49 info
Change: +$7.49 (+7%) info
Market Cap: $5.043B info
MANE
May 05, 2026, 9:39 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $114.50
Real-time Price: $118.49 info
Change: +$3.99 (+3%) info
Market Cap: $5.043B info
MANE
May 05, 2026, 7:44 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
7
Price at Filing: $114.50
Real-time Price: $118.49 info
Change: +$3.99 (+3%) info
Market Cap: $5.043B info
MANE
May 01, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $100.97
Real-time Price: $118.49 info
Change: +$17.52 (+17%) info
Market Cap: $5.043B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets